API quality – Page 12

API stability failure during incoming testing – root cause investigation framework

Framework for Investigating API Stability Failures during Incoming Testing Natural variability in Active Pharmaceutical Ingredients (APIs) can pose significant challenges in ensuring quality and compliance, especially during incoming testing. A…

Polymorphic form inconsistency during supplier change – root cause investigation framework

Framework for Investigating Polymorphic Form Inconsistency During Supplier Changes In pharmaceutical manufacturing, the inconsistency in polymorphic forms during supplier changes can lead to significant quality challenges. When a new supplier…

API stability failure during regulatory inspection – inspection questions regulators ask

Addressing API Stability Failures During Regulatory Inspections API stability failures that surface during regulatory inspections can create significant disruptions in pharmaceutical manufacturing. Such scenarios not only jeopardize compliance but also…

API stability failure during supplier change – root cause investigation framework

Framework for Investigating API Stability Failures Amid Supplier Changes In the fast-evolving pharmaceutical landscape, changes in suppliers for Active Pharmaceutical Ingredients (APIs) can lead to significant challenges, particularly concerning API…

Polymorphic form inconsistency during deviation investigation – root cause investigation framework

Framework for Investigating Polymorphic Form Inconsistency in Pharmaceuticals Polymorphic form inconsistency poses significant risks in pharmaceutical manufacturing, particularly concerning active pharmaceutical ingredients (APIs) and their performance. When encountering deviations related…

API stability failure during regulatory inspection – regulatory impact assessment

Assessing the Impact of API Stability Failures During Regulatory Inspections Suboptimal stability of Active Pharmaceutical Ingredients (APIs) is a critical issue that can arise unexpectedly during regulatory inspections, leading to…

Particle size variability impacts performance during supplier change – regulatory impact assessment

Understanding the Impact of Particle Size Variability during Supplier Changes on Drug Performance The introduction of new suppliers or raw materials is a common challenge in pharmaceutical manufacturing. A significant…

API assay variability exceeds trend limits during stability studies – inspection questions regulators ask

Investigation of API Assay Variability Surpassing Trend Limits in Stability Studies The pharmaceutical industry faces constant scrutiny regarding the integrity of its data and the quality of its Active Pharmaceutical…

API stability failure during incoming testing – preventing batch rejection and recall

Addressing API Stability Failures during Incoming Testing to Prevent Batch Rejection and Recalls An API stability failure during incoming testing can lead to significant quality issues and operational disruptions in…

Impurity profile drift detected during deviation investigation – regulatory impact assessment

Investigating Impurity Profile Drift: An Essential Guide for Regulatory Compliance In pharmaceutical manufacturing, the integrity of raw materials and APIs is paramount. An impurity profile drift detected during a deviation…

API assay variability exceeds trend limits during incoming testing – regulatory impact assessment

Assessing API Assay Variability That Exceeds Trend Limits During Incoming Testing In the realm of pharmaceutical manufacturing, variabilities in active pharmaceutical ingredients (APIs) can critically impact product quality and compliance…

Impurity profile drift detected during deviation investigation – preventing batch rejection and recall

Addressing Impurity Profile Drift in Pharmaceutical Manufacturing Investigations Impurity profile drift can lead to significant quality control issues in pharmaceutical manufacturing, specifically during the production of Active Pharmaceutical Ingredients (APIs)…